Vanda Pharmaceuticals | VNDA - Passifs Courants





Passifs Courants Changement Date
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Esperion Therapeutics USD 300.36M 451K 2026-03
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Insmed USD 361.01M 107.87M 2026-03
J&J USD 57.72B 3.59B 2026-03
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
Ligand Pharmaceuticals USD 40.67M 3.22M 2026-03
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Moderna USD 2.4B 408M 2026-03
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.43T 180.65B 2026-03
Teva Pharmaceutical Industries USD 13.53B 76M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Veracyte USD 56.11M 3.82M 2026-03